Long-Term Safety and Effectiveness of Canakinumab in Patients with MKD/HIDS: Interim Analysis of the RELIANCE Registry
Data from this interim analysis of a unique registry of patients with a rare disease support the long-term safety and effectiveness of the IL-1-blocking agent canakinumab for the treatment of MKD/HIDS.
Authors
- Prasad T. Oommen (ORCID: https://orcid.org/0000-0003-2893-7252)
- J. Weber-Arden
- Tilmann Kallinich (ORCID: https://orcid.org/0000-0003-2404-9397)
- Jasmin Beate Kuemmerle-Deschner (ORCID: https://orcid.org/0000-0002-6365-6598)
- Jürgen Rech (ORCID: https://orcid.org/0000-0002-2569-2029)
- Norbert Blank (ORCID: https://orcid.org/0000-0002-9419-1690)
Institutions
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- Leibniz Association (DE)
- Novartis (Germany) (DE)
- Universitätsklinikum Erlangen (DE)
- German Rheumatism Research Centre (DE)
- University Children's Hospital Tübingen (DE)
- Comprehensive Cancer Center Erlangen (DE)
- Heinrich Heine University Düsseldorf (DE)
- Charité - Universitätsmedizin Berlin (DE)
- University of Tübingen (DE)
Publication Details
- Journal
- Rheumatology and Therapy
- Published
- 2024-12-26
- DOI
- https://doi.org/10.1007/s40744-024-00733-7
- Citations
- 3
- Primary Topic
- Immunodeficiency and Autoimmune Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.72
Funders
- Novartis Pharma